What we do Vilin Bio Med Ltd manufactures a diverse range of pharmaceutical products including Beta-Lactam and Non-Beta-Lactam tablets, capsules, syrups, and external preparations. |
Founded in 2,005 |
Market share A growing player in India's pharmaceutical manufacturing space, focusing on niche Beta-Lactam and general medicines segments. |
Problem solved Provides effective medicines for bacterial infections and general diseases, addressing healthcare needs with tablet, capsule, syrup, and topical formulations. |
Top clients or who we serve Serves domestic pharmaceutical markets targeting hospitals, clinics, and pharmacies; B2B and B2C pharmaceutical supply. |
Key management Mr. Y Madhusudhan Reddy (Managing Director), Ms. Prasanna Lakshmi Venna (Whole-Time Director) |
Our journey and innovations Founded in 2005; expanded Beta-Lactam capacity in 2007; acquired 1000+ drug approvals in 2010; IPO raised Rs. 12 crore in 2023. |
Where we operate Domestic operations with manufacturing and R&D facilities in Uttarakhand, India. |
Top products or what we offer Oral liquids, tablets, capsules for Beta-Lactam and Non-Beta-Lactam drugs, and topical ointments, creams, lotions. |
Top brands - |
Raw materials needed Active pharmaceutical ingredients primarily Beta-Lactam and Non-Beta-Lactam compounds, excipients for formulations. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue largely recurring through pharmaceutical product sales to healthcare providers and pharmacies. |
Our industry position Emerging pharmaceutical manufacturer with a focus on Beta-Lactam antibiotics and general formulations, catering to Indian market demands. |
Financial highlights FY 2024-25 revenue Rs. 14.81 Crore; PAT Rs. 0.22 Crore, showing profit growth from previous year. |
Geographical revenue split - |
Order book - |
Whats driving growth Product portfolio expansion, enhanced regulatory approvals, focus on Beta-Lactam formulations, and new commercial production capacity. |
Our future plans Explore new business opportunities to boost growth and profitability; maintain competitiveness via R&D investment. |
Our green promise - |
Our people and values Committed to employee productivity, ethical governance, and compliance with applicable laws and standards. |
Key challenges ahead Market competition, regulatory compliance, raw material sourcing, and scaling production capacity while maintaining quality. |
Interesting facts Holds approvals for over 1000 drug molecules; listed on NSE SME board in 2023. |
Risks and strategy Focused on internal controls, risk management, and adherence to corporate governance to mitigate operational and financial risks. |
